Walvax Biotechnology Hits Day High with Strong 3.85% Intraday Surge

Walvax Biotechnology Co., Ltd. has experienced a notable increase of 3.85% on May 25, 2026, reaching an intraday high of CNY 14.32. This performance stands out against the backdrop of the China Shanghai Composite, which recorded a modest gain of 0.96% on the same day. Over the past month, Walvax has shown impressive growth, with a 20.45% increase, significantly outperforming the broader market's 1.78% rise. Year-to-date, the stock has delivered a robust return of 31.16%, compared to the China Shanghai Composite's 4.63%. Despite the recent positive momentum, the company has faced challenges in long-term growth, with net sales increasing at an annual rate of only 4.90% over the last five years. However, it reported a remarkable net profit growth of 4082.41% in its latest quarterly results, indicating a turnaround in performance. With a market capitalization of CNY 22,295 million, Walvax operates within the Pharmaceuticals & Biotechnology sector, showcasing a high dividend yield of 0.29% and a return on equity of 3.40%.